文献速递泌尿男性生殖肿瘤

靶向uPAR的多模态分子成像用于尿路上皮癌诊断、切除与监测

A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
PubMed 文献 · Eur J Cancer · 2021-02-06

尿路上皮癌五年复发率高达30-78%,术后需终身内镜监测。研究以靶向uPAR的人源化单抗MNPR-101偶联IRDye800CW,在细胞与小鼠模型中验证近红外荧光及光声三维成像效果,显示可特异性勾勒肿瘤且肿瘤背景比达6.8,与对照差异显著(p<0.0001)。

要点

  • uPAR在尿路上皮癌肿瘤-间质界面高表达,EpCAM表达于上皮细胞。
  • MNPR-101-IRDye800CW对uPAR结构域2-3具皮摩尔级亲和力。
  • 近红外荧光成像肿瘤背景比高达6.8,与对照差异显著(p<0.0001)。

核心结论

  • MNPR-101-IRDye800CW适用于尿路上皮癌多模态成像,尚待临床转化。

研究设计与样本

  • 在人尿路上皮癌石蜡组织与细胞系中检测uPAR和EpCAM表达。
  • 将靶向uPAR的人源化单抗MNPR-101偶联IRDye800CW,体外用表面等离子共振和细胞结合实验验证结合。
  • 在BALB/c裸鼠皮下UM-UC-3luc2模型行近红外荧光与光声三维成像,并在转移性原位模型验证转化潜力。
  • 对照使用infliximab-IRDye800CW和rituximab-IRDye800CW。

主要发现

  • 尿路上皮癌在肿瘤-间质界面显示显著uPAR表达,上皮细胞表达EpCAM。
  • uPAR和EpCAM分别在6/7和4/7的尿路上皮癌细胞系中表达。
  • MNPR-101-IRDye800CW对uPAR结构域2-3具皮摩尔级亲和力。
  • 体内荧光成像可特异性勾勒皮下与原位肿瘤,肿瘤背景比高达6.8,与对照差异显著(p<0.0001)。
  • 光声三维深度成像证实MNPR-101-IRDye800CW在肿瘤内分布均匀。

临床怎么用

  • 该多模态成像策略有望改善尿路上皮癌的诊断、切除与术后监测。

局限性

  • 研究仅在细胞与小鼠模型中进行,尚待临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: With a 5-year recurrence rate of 30-78%, urothelial cell carcinoma (UCC) rates amongst the highest of all solid malignancies. Consequently, after transurethral resection, patients are subjugated to life-long endoscopic surveillance. A multimodal near-infrared (NIR) fluorescence-based imaging strategy can improve diagnosis, resection and surveillance, hence increasing quality of life. METHODS: Expression of urokinase plasminogen activator receptor (uPAR) and epithelial cell adhesion molecule (EpCAM) are determined on paraffin-embedded human UCC using immunohistochemistry and on UCC cell lines by flow cytometry. MNPR-101, a humanised monoclonal antibody targeting uPAR is conjugated to IRDye800CW and binding is validated in vitro using surface plasmon resonance and cell-based binding assays. In vivo NIR fluorescence and photoacoustic three-dimensional (3D) imaging are performed with subcutaneously growing human UM-UC-3luc2 cells in BALB/c-nude mice. The translational potential is confirmed in a metastasising UM-UC-3luc2 orthotopic mouse model. Infliximab-IRDye800CW and rituximab-IRDye800CW are used as controls. RESULTS: UCCs show prominent uPAR expression at the tumour-stroma interface and EpCAM on epithelial cells. uPAR and EpCAM are expressed by 6/7 and 4/7 UCC cell lines, respectively. In vitro, MNPR-101-IRDye800CW has a picomolar affinity for domain 2-3 of uPAR. In vivo fluorescence imaging with MNPR-101-IRDye800CW, specifically delineates both subcutaneous and orthotopic tumours with tumour-to-background ratios reaching as high as 6.8, differing significantly from controls (p < 0.0001). Photoacoustic 3D in depth imaging confirms the homogenous distribution of MNPR-101-IRDye800CW through the tumour. CONCLUSIONS: MNPR-101-IRDye800CW is suitable for multimodal imaging of UCC, awaiting clinical translation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Baart VM, van der Horst G, Deken MM, et al. A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma. Eur J Cancer. 2021. PMID: 33561783. doi:10.1016/j.ejca.2021.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。